Replimune Group Inc (Symbol: REPL) shares recently traded at $11.00, surpassing the average analyst 12-month target price of $10.67. This price movement could prompt analysts to either downgrade their valuations or adjust target prices higher, depending on the company’s fundamental developments.
The average target is based on six different analyst projections, with a range spanning from $2.00 to $17.00 and a standard deviation of $5.465. Currently, the analyst ratings for Replimune include three “Strong Buy,” five “Hold,” and one “Strong Sell,” resulting in an average rating of 2.56, where 1 signifies “Strong Buy” and 5 indicates “Strong Sell.”
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
